A Phase 2 interventional study of Brexpiprazole and Sertraline in Stress Disorders, Post-Traumatic, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 54 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-12-08.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sertraline in Stress Disorders, Post-Traumatic — none open to participants now, none under way, none of them phase 3. Sertraline · Stress Disorders, Post-Traumatic.
Among the 22 studies testing sertraline in Stress Disorders, Post-Traumatic, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 2, and was the 18th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →None of the 22 studies testing sertraline in Stress Disorders, Post-Traumatic is open now. The open studies under Stress Disorders, Post-Traumatic, anywhere →
Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5 · Phase 4 11
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 336 is above the median of 69 across 2,201 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 80 across the 21 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd.: 3 open now, 3 under way, 3 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 3 in phase 2, and was the 1st registered.
Otsuka Holdings Co., Ltd.’s Stress Disorders, Post-Traumatic studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sertraline in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 11 in Stress Disorders, Post-Traumatic:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy with Zoloft (sertraline) in adults with PTSD.
This trial is designed to assess the efficacy, safety and tolerability of flexible dose brexpiprazole as monotherapy or as combination therapy with Zoloft (Sertraline) in adult participants with PTSD.
This study will consist of a continuous 12-week, double-blind treatment period with a 14-day follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants were administered oral brexpiprazole initial dose of 0.5 milligram (mg)/day plus sertraline initial dose of 50 mg/day. The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo based on dose titration/adjustment up to Week 12.
Drug: Brexpiprazole · Drug: Sertraline · Drug: Sertraline Matching Placebo
Participants were administered oral brexpiprazole initial dose of 0.5 mg/day The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo up to Week 12.
Drug: Brexpiprazole · Drug: Sertraline Matching Placebo
Participants were administered oral sertraline initial dose of 50 mg/day. The dose was up titrated to sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received brexpiprazole matching placebo and sertraline matching placebo based on dose titration/adjustment up to Week 12.
Drug: Sertraline · Drug: Brexpiprazole Matching Placebo · Drug: Sertraline Matching Placebo
Participants received oral brexpiprazole matching placebo tablet and oral sertraline matching placebo capsules up to Week 12.
Drug: Brexpiprazole Matching Placebo · Drug: Sertraline Matching Placebo
Brexpiprazole oral tablets.
Also known as: OPC-34712, OPC-331
Sertraline oral capsules.
Also known as: Zoloft
Brexpiprazole matching placebo oral tablets.
Sertraline matching placebo oral capsules.
Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score
CAPS-5:clinician-rated, structured interview to assess PTSD diagnostic status, symptoms severity as defined by DSM-5. CAPS-5 Past Week version of scale was completed at Baseline and at all visits after Baseline. CAPS-5 was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B:Intrusion symptoms (5 items); Category C:Avoidance symptoms (2 items); Category D:Cognition and mood symptoms (7 items); Category E:Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B,C,D,E. Each symptom was scored 0 (Absent) to 4 (Extreme/incapacitating), to yield a score with range 0-80. Higher scores=worse outcome. Mixed model repeated measure (MMRM) was used for analysis.
Time frame: Baseline, Week 12
Participants took part in the study at 48 investigative sites in the United States from 26 January 2017 to 12 November 2018.
| Milestone | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo |
|---|---|---|---|---|
| Started | 82 | 75 | 81 | 83 |
| Safety sample | 80 | 75 | 79 | 82 |
| Intent to treat (itt) sample | 79 | 72 | 77 | 80 |
| Completed | 58 | 50 | 59 | 64 |
| Not completed | 24 | 25 | 22 | 19 |
| Withdrew: Adverse event | 6 | 7 | 4 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 6 | 5 | 5 | 6 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 10 | 11 | 6 |
| Withdrew: Withdrawal by caregiver | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 1 |
CAPS-5:clinician-rated, structured interview to assess PTSD diagnostic status, symptoms severity as defined by DSM-5. CAPS-5 Past Week version of scale was completed at Baseline and at all visits after Baseline. CAPS-5 was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B:Intrusion symptoms (5 items); Category C:Avoidance symptoms (2 items); Category D:Cognition and mood symptoms (7 items); Category E:Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B,C,D,E. Each symptom was scored 0 (Absent) to 4 (Extreme/incapacitating), to yield a score with range 0-80. Higher scores=worse outcome. Mixed model repeated measure (MMRM) was used for analysis.
| score on a scale | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo |
|---|---|---|---|---|
| Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score | -16.4 ± 1.43 | -12.2 ± 1.57 | -11.4 ± 1.46 | -10.5 ± 1.40 |
Collected over From the first dose of the study drug up to 14 days after the last dose (Up to Week 14). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole + Sertraline | 0/80 (0%) | 2/80 (2.5%) | 47/80 (58.8%) |
| Brexpiprazole | 0/75 (0%) | 1/75 (1.3%) | 42/75 (56%) |
| Sertraline | 0/79 (0%) | 0/79 (0%) | 46/79 (58.2%) |
| Placebo | 1/82 (1.2%) | 4/82 (4.9%) | 43/82 (52.4%) |
| Event | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo |
|---|---|---|---|---|
| Animal biteInjury, poisoning and procedural complications | 0/80 | 1/75 | 0/79 | 0/82 |
| Back painMusculoskeletal and connective tissue disorders | 1/80 | 0/75 | 0/79 | 1/82 |
| Suicide attemptPsychiatric disorders | 1/80 | 0/75 | 0/79 | 0/82 |
| Chest painGeneral disorders | 0/80 | 0/75 | 0/79 | 1/82 |
| Bile duct stoneHepatobiliary disorders | 0/80 | 0/75 | 0/79 | 1/82 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/80 | 0/75 | 0/79 | 1/82 |
| Event | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/80 | 1/75 | 16/79 | 4/82 |
| AkathisiaNervous system disorders | 5/80 | 10/75 | 3/79 | 2/82 |
| Dry mouthGastrointestinal disorders | 5/80 | 6/75 | 10/79 | 7/82 |
| Weight increaseInvestigations | 10/80 | 6/75 | 1/79 | 7/82 |
| SomnolenceNervous system disorders | 8/80 | 5/75 | 3/79 | 7/82 |
| Upper respiratory tract infectionInfections and infestations | 3/80 | 7/75 | 7/79 | 7/82 |
| DiarrhoeaGastrointestinal disorders | 5/80 | 3/75 | 7/79 | 5/82 |
| HeadacheNervous system disorders | 6/80 | 4/75 | 7/79 | 7/82 |
| FatigueGeneral disorders | 2/80 | 6/75 | 4/79 | 0/82 |
| Decreased appetiteMetabolism and nutrition disorders | 6/80 | 5/75 | 1/79 | 1/82 |
Randomized Sample included all participants randomized into this trial.
| Age, Continuous(years) | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 38.4 ± 11.9 | 39.3 ± 10.6 | 38.6 ± 10.9 | 40.3 ± 11.0 | 39.2 ± 11.1 |
| Sex: Female, Male(Participants) | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo | Total |
|---|---|---|---|---|---|
| Female | 51 | 49 | 51 | 48 | 199 |
| Male | 31 | 26 | 30 | 35 | 122 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo | Total |
|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 1 | 0 | 2 | 4 |
| Race — Asian | 1 | 2 | 0 | 1 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 0 | 2 |
| Race — Black or African American | 21 | 23 | 22 | 26 | 92 |
| Race — White | 55 | 43 | 53 | 46 | 197 |
| Race — Other | 3 | 5 | 6 | 8 | 22 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 13 | 11 | 11 | 14 | 49 |
| Ethnicity — Not Hispanic or Latino | 68 | 64 | 70 | 69 | 271 |
| Ethnicity — Other | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Brexpiprazole + Sertraline | Brexpiprazole | Sertraline | Placebo | Total |
|---|---|---|---|---|---|
| United States | 82 | 75 | 81 | 83 | 321 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jan 2017 to primary completion in Nov 2018, 21 months.
Results were first posted in Dec 2021, 3 years after primary completion. A results delay was requested in Oct 2019.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 21 months is close to that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brexpiprazole · Sertraline
Stress Disorders, Post-Traumatic →
Otsuka Pharmaceutical Development & Commercialization, Inc. →